INTELLIA THERAPEUTICS, INC. (NTLA) Operating income 2016–2025
INTELLIA THERAPEUTICS, INC. (NTLA) annual operating income history from SEC filings — each fiscal year as reported.
-$441.0MFY2025 · since FY2016: -$32.2M → -$441.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$441.0M | +17.5% |
| FY2024 | -$534.3M | -3.7% |
| FY2023 | -$515.3M | -12.5% |
| FY2022 | -$458.2M | -71.1% |
| FY2021 | -$267.9M | -96.1% |
| FY2020 | -$136.6M | -28.4% |
| FY2019 | -$106.4M | -17.1% |
| FY2018 | -$90.9M | -30.6% |
| FY2017 | -$69.6M | -116.3% |
| FY2016 | -$32.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More NTLA financial trends
NTLA RevenueNTLA Net incomeNTLA Net marginNTLA Gross profitNTLA Gross marginNTLA Operating marginNTLA Operating cash flowNTLA Free cash flowNTLA Capital expendituresNTLA Return on equityNTLA Stock buybacksNTLA Dividends paidNTLA Total assetsNTLA Total liabilitiesNTLA Shareholders’ equityNTLA overview →